| Catherine Anne Morrison, MD, MPH | |
|
3220 Providence Dr Ste 3080, Anchorage, AK 99508-4679 | |
| (907) 375-8785 | |
| Not Available |
| Full Name | Catherine Anne Morrison |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 19 Years |
| Location | 3220 Providence Dr Ste 3080, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184954265 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 120497 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Alaska Medical Center | Anchorage, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alaska Trauma And Acute Care Surgery Llc | 4880828797 | 10 |
News Archive
Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.
Lately, there has been considerable debate about the soaring prices of specialty drugs, which are aimed at difficult-to-treat diseases.
Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications , according to two new studies in Gastroenterology, the official journal of the American Gastroenterological Association. Immunosuppressants are commonly used in the treatment of IBD.
Hyaluronic acid (HA) fillers are a popular treatment for facial lines and wrinkles, but early degradation of fillers may limit how long their effects last. Experimental evidence supports a simple technique for prolonging the effects of HA dermal fillers: using them together with botulinum toxin, reports a paper in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).
The combination of two obesity-related genetic variations may be associated with an increased body mass index (BMI) among severely obese patients undergoing bariatric weight loss surgery, according to a report in the March issue of Archives of Surgery.
› Verified 4 days ago
| Entity Name | Alaska Trauma & Acute Care Surgery Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982047437 PECOS PAC ID: 4880828797 Enrollment ID: O20131009000258 |
News Archive
Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.
Lately, there has been considerable debate about the soaring prices of specialty drugs, which are aimed at difficult-to-treat diseases.
Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications , according to two new studies in Gastroenterology, the official journal of the American Gastroenterological Association. Immunosuppressants are commonly used in the treatment of IBD.
Hyaluronic acid (HA) fillers are a popular treatment for facial lines and wrinkles, but early degradation of fillers may limit how long their effects last. Experimental evidence supports a simple technique for prolonging the effects of HA dermal fillers: using them together with botulinum toxin, reports a paper in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).
The combination of two obesity-related genetic variations may be associated with an increased body mass index (BMI) among severely obese patients undergoing bariatric weight loss surgery, according to a report in the March issue of Archives of Surgery.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Catherine Anne Morrison, MD, MPH 3220 Providence Dr Ste 3080, Anchorage, AK 99508-4679 Ph: (907) 375-8785 | Catherine Anne Morrison, MD, MPH 3220 Providence Dr Ste 3080, Anchorage, AK 99508-4679 Ph: (907) 375-8785 |
News Archive
Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.
Lately, there has been considerable debate about the soaring prices of specialty drugs, which are aimed at difficult-to-treat diseases.
Certain patients with inflammatory bowel disease (IBD) may have an increased risk of skin cancer, which is intensified by the use of immunosuppressant medications , according to two new studies in Gastroenterology, the official journal of the American Gastroenterological Association. Immunosuppressants are commonly used in the treatment of IBD.
Hyaluronic acid (HA) fillers are a popular treatment for facial lines and wrinkles, but early degradation of fillers may limit how long their effects last. Experimental evidence supports a simple technique for prolonging the effects of HA dermal fillers: using them together with botulinum toxin, reports a paper in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).
The combination of two obesity-related genetic variations may be associated with an increased body mass index (BMI) among severely obese patients undergoing bariatric weight loss surgery, according to a report in the March issue of Archives of Surgery.
› Verified 4 days ago
Dr. Bijiibaa' K Garrison, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 520-390-8275 | |
Dr. Jeffrey Charles Congdon, MD Surgery Medicare: Medicare Enrolled Practice Location: 2925 Debarr Rd, Anchorage, AK 99508 Phone: 907-257-4869 | |
Kevin Joseph Stange, MD Surgery Medicare: Medicare Enrolled Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-563-2662 | |
Dr. Regina Sutton Chennault, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2751 Debarr Rd, Suite 280a, Anchorage, AK 99508 Phone: 907-222-6888 Fax: 907-222-6884 | |
Mark James Thorndike, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-563-2662 | |
Dr. Priya Patel, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 4001 Laurel St Ste 204, Anchorage, AK 99508 Phone: 907-562-8346 | |
Dr. Madhu Prasad, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2925 Debarr Rd Ste D350, Anchorage, AK 99508 Phone: 907-276-3676 Fax: 907-276-3679 |